GOSS News and Press, Gossamer Bio Inc. From 08/09/19

The following slide deck was published by Gossamer Bio, Inc. in conjunction with this Read more ...

Gossamer Bio (NASDAQ: GOSS ): Q2 GAAP EPS of -$0.74 misses by $0.18 . More news on: Gossamer Bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

– Immuno-oncology candidate, GB1275, advances to clinic for selected solid tumor types – – Five active clinical trials across four clinical programs, with data readouts for all four programs expected in 2020 – – Company to host conference call to...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its second quarter 2019 financial res...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

Thinly traded AnaptysBio ( ANAB +2.3% ) is up on below-average volume on the heels of updated results from a proof-of-concept Phase 2b clinical trial evaluating a single intravenous dose of lead candidate etokimab in 25 adults with severe eosinophilic asthma. The data were presented at E...

According to Aerpio Pharmaceuticals (ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readouts from ...

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a...

Gossamer Bio, Inc. (GOSS) Q1 2019 Results Earnings Conference Call May 14, 2019, 08:30 AM ET Company Participants Bryan Giraudo - CFO Sheila Gujrathi - Co-Founder and CEO Conference Call Participants Ying Huang - Bank of America/Merrill Lynch Joseph Schwartz - SVB Leerink ...